Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 ΔV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin (Q61641053)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 ΔV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin	article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

molecular medicine

0 references

Escherichia coli

1 reference

based on heuristic

inferred from title

Antonella Caputo

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Riccardo Gavioli

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Egidio Brocca-Cofano

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Arianna Castaldello

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Rebecca Voltan

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Aurelio Cafaro

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Indresh K Srivastava

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Susan W Barnett

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

language of work or name

0 references

publication date

15 January 2008

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

number of pages

14

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

26

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1214-1227

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

HIV vaccine design and the neutralizing antibody problem

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Clinical research. A setback and an advance on the AIDS vaccine front

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Antibody vs. HIV in a clash of evolutionary titans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Progress and obstacles in the development of an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Problems and emerging approaches in HIV/AIDS vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Recent advances in the development of HIV-1 Tat-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Rational vaccine strategies against AIDS: background and rationale

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Criteria for selection of HIV vaccine candidates—general principles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Introduction: rational vaccine strategies against AIDS

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant ΔV2 Env

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Candidate HIV-1 Tat vaccine development: from basic science to clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

HIV-1 Tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Perils at mucosal front lines for HIV and SIV and their hosts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Mucosal HIV vaccines: where are we now?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Progress towards an AIDS mucosal vaccine: an overview

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

HIV swiftly guts the immune system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

New generation of mucosal adjuvants for the induction of protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Enhancement of vaccine potency by fusing modified LTK63 into human papillomavirus type 16 chimeric virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Caprine herpesvirus 1 vaccine with the LTK63 mutant as a mucosal adjuvant induces strong protection against genital infection in goats.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

The acquired immune response to the mucosal adjuvant LTK63 imprints the mouse lung with a protective signature.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Recent advances in immunological adjuvants: the development of particulate antigen delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Induction of Broad and Potent Anti-Human Immunodeficiency Virus Immune Responses in Rhesus Macaques by Priming with a DNA Vaccine and Boosting with Protein-Adsorbed Polylactide Coglycolide Microparticles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Candidate HIV-1 gp140ΔV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Preparation and Characterization of Innovative Protein-coated Poly(Methylmethacrylate) Core-shell Nanoparticles for Vaccine Purposes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Therapeutic vaccination reduces HIV sequence variability

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Intranasal immunization with tetanus toxoid and CNF1 as a new mucosal adjuvant protects BALB/c mice against lethal challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Neutralizing antibodies against HIV -- back in the major leagues?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

HIV-1 and the hijacking of dendritic cells: a tug of war.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Induction of optimal immune responses against human immunodeficiency virus at mucosal portals of entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2007.12.030

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q61641053&oldid=1953488934"